Panel Discussion: Empowering Combination Strategies to Target RAS Mutant Cancers: The Future of Oncology Therapy
Time: 4:30 pm
day: Day Two
- What are the key factors to consider ensuring successful translation from discovery to clinic?
- The importance of moving beyond G12C – with the abundance of research surrounding G12C mutation, how and why should we be pushing for new avenues to explore?
- Technology, platforms & collaborations – what does the RAS community need in order to progress and produce effective, quality and safe RAS mutant cancer therapies?